Abstract
Type 2 Diabetes mellitus (T2DM) is one of the major non-communicable diseases worldwide. Interleukin-17 (IL-17, also known as IL-17A) is a key cytokine that links T cell activation to neutrophil mobilization and activation. In the cytokine storm, up-regulation of T-helper 17 cell cytokine IL-17A, and maybe also IL-17F, is primarily responsible for the immunopathology. This study aims to assess the Interleukin-17 A levels among the susceptibility of T2DM Iraqi diabetic patients as well as to determine the Interleukin-17 A levels among those patients and controls. A total of 70 participants 50 confirmed type 2diabetic patients and 20 apparently healthy individuals as controls were selected using a convenient sampling method. Evaluation of serum levels of IL-17A were performed using by enzyme-linked immunosorbent assay technique (ELISA) using a Human- IL-17A kit. (Elabscience Company /china). The results of the current study indicated that the levels of this interleukin were higher in the sera of patients with type 2 diabetes compared to healthy controls, although there were no significant differences, in patients (243.7233±38.45944), vs. controls (148.8930±11.79280), P= 0.135. We conclude that there may be a correlation between high levels of IL-17A and T2DM.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
